Suppr超能文献

药物遗传学的前景与挑战:研究设计、方法学及统计学问题综述

Promises and challenges of pharmacogenetics: an overview of study design, methodological and statistical issues.

作者信息

Ross Stephanie, Anand Sonia S, Joseph Philip, Paré Guillaume

机构信息

Population Health Research Institute, Hamilton Health Sciences, McMaster University , Hamilton, Ontario L8L 2X2 , Canada.

出版信息

JRSM Cardiovasc Dis. 2012 Apr 5;1(1):cvd.2012.012001. doi: 10.1258/cvd.2012.012001.

Abstract

Pharmacogenetics is the study of inherited variation in drug response. The goal of pharmacogenetics is to develop novel ways of maximizing drug efficacy and minimizing toxicity for individual patients. Personalized medicine has the potential to allow for a patient's genetic information to predict optimal dosage for a drug with a narrow therapeutic index, to select the most appropriate pharmacological agent for a given patient and to develop cost-effective treatments. Although there is supporting evidence in favour of pharmacogenetics, its adoption in clinical practice has been slow because of sometimes conflicting findings among studies. This failure to replicate findings may result from a lack of high-quality pharmacogenetic studies, as well as unresolved methodological and statistical issues. The objective of this review is to discuss the benefits of incorporating pharmacogenetics into clinical practice. We will also address outstanding methodological and statistical issues that may lead to heterogeneity among reported pharmacogenetic studies and how they may be addressed.

摘要

药物遗传学是对药物反应中遗传变异的研究。药物遗传学的目标是开发新方法,以实现个体患者药物疗效最大化和毒性最小化。个性化医疗有可能利用患者的遗传信息预测治疗指数窄的药物的最佳剂量,为特定患者选择最合适的药物,并开发具有成本效益的治疗方法。尽管有支持药物遗传学的证据,但由于研究结果有时相互矛盾,其在临床实践中的应用进展缓慢。研究结果无法重复可能是由于缺乏高质量的药物遗传学研究,以及尚未解决的方法学和统计学问题。本综述的目的是讨论将药物遗传学纳入临床实践的益处。我们还将探讨可能导致所报道的药物遗传学研究存在异质性的突出方法学和统计学问题,以及如何解决这些问题。

相似文献

1
Promises and challenges of pharmacogenetics: an overview of study design, methodological and statistical issues.
JRSM Cardiovasc Dis. 2012 Apr 5;1(1):cvd.2012.012001. doi: 10.1258/cvd.2012.012001.
2
Methodological quality of pharmacogenetic studies: issues of concern.
Stat Med. 2008 Dec 30;27(30):6547-69. doi: 10.1002/sim.3420.
3
Pharmacogenomics in Stroke and Cardiovascular Disease: State of the Art.
Stroke. 2023 Jan;54(1):270-278. doi: 10.1161/STROKEAHA.122.037717. Epub 2022 Nov 3.
4
The future of Cochrane Neonatal.
Early Hum Dev. 2020 Nov;150:105191. doi: 10.1016/j.earlhumdev.2020.105191. Epub 2020 Sep 12.
5
Clinical pharmacogenetics and potential application in personalized medicine.
Curr Drug Metab. 2008 Oct;9(8):738-84. doi: 10.2174/138920008786049302.
6
Pharmacogenetics of osteoporosis: what is the evidence?
Curr Osteoporos Rep. 2012 Sep;10(3):221-7. doi: 10.1007/s11914-012-0110-7.
7
Facilitators and Barriers to the Adoption of Pharmacogenetic Testing in an Inner-City Population.
Pharmacotherapy. 2018 Feb;38(2):205-216. doi: 10.1002/phar.2077. Epub 2018 Jan 21.
8
Pharmacogenetics of antipsychotics: recent progress and methodological issues.
Expert Opin Drug Metab Toxicol. 2013 Feb;9(2):183-91. doi: 10.1517/17425255.2013.736964. Epub 2012 Dec 1.
9
Pharmacogenetics: A strategy for personalized medicine for autoimmune diseases.
Clin Genet. 2018 Mar;93(3):481-497. doi: 10.1111/cge.13186.

引用本文的文献

2
Pharmacogenetics of tamoxifen in breast cancer patients of African descent: Lack of data.
Clin Transl Sci. 2024 Mar;17(3):e13761. doi: 10.1111/cts.13761.
3
Promises and challenges in pharmacoepigenetics.
Camb Prism Precis Med. 2023 Feb 9;1:e18. doi: 10.1017/pcm.2023.6. eCollection 2023.
4
Application of Pharmacogenomics Testing in a Community-based Facility.
Hosp Pharm. 2023 Feb;58(1):98-105. doi: 10.1177/00185787221134693. Epub 2022 Nov 9.
6
From pharmacogenetics to pharmaco-omics: Milestones and future directions.
HGG Adv. 2022 Mar 16;3(2):100100. doi: 10.1016/j.xhgg.2022.100100. eCollection 2022 Apr 14.
7
Pharmacogenetic interventions to improve outcomes in patients with multimorbidity or prescribed polypharmacy: a systematic review.
Pharmacogenomics J. 2022 Mar;22(2):89-99. doi: 10.1038/s41397-021-00260-6. Epub 2022 Feb 22.
8
Impact of study design and statistical model in pharmacogenetic studies with gene-treatment interaction.
CPT Pharmacometrics Syst Pharmacol. 2021 Apr;10(4):340-349. doi: 10.1002/psp4.12624.
9
Pharmacogenomics Biomarker Discovery and Validation for Translation in Clinical Practice.
Clin Transl Sci. 2021 Jan;14(1):113-119. doi: 10.1111/cts.12869. Epub 2020 Oct 22.

本文引用的文献

3
Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C9 and VKORC1 genotypes and warfarin dosing.
Clin Pharmacol Ther. 2011 Oct;90(4):625-9. doi: 10.1038/clpt.2011.185. Epub 2011 Sep 7.
5
Pharmacogenetic testing: time for clinical practice guidelines.
Clin Pharmacol Ther. 2011 Jun;89(6):924-7. doi: 10.1038/clpt.2011.18. Epub 2011 Apr 20.
6
Methodological quality in pharmacogenetic studies with binary assessment of treatment response: a review.
Pharmacogenet Genomics. 2011 May;21(5):243-50. doi: 10.1097/FPC.0b013e32834300fb.
8
Effects of CYP2C19 genotype on outcomes of clopidogrel treatment.
N Engl J Med. 2010 Oct 28;363(18):1704-14. doi: 10.1056/NEJMoa1008410. Epub 2010 Aug 29.
9
Statistical analysis strategies for association studies involving rare variants.
Nat Rev Genet. 2010 Nov;11(11):773-85. doi: 10.1038/nrg2867. Epub 2010 Oct 13.
10
Economic efficiency of genetic screening to inform the use of abacavir sulfate in the treatment of HIV.
Pharmacoeconomics. 2010;28(11):1025-39. doi: 10.2165/11535540-000000000-00000.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验